semaglutide may 2025 fda shortage status january As of February 21, 2025, the updated its drug list Ozempic and Wegovy: How Semaglutide

Furthermore, in obese individuals with sleep disorders, the secretion and activity of GLP-1 RA are decreased, which can lead to abnormal sugar metabolism and weight gain, thereby exacerbating OSA [63, 77, 78]

You can start increasing your dose after four weeks

This phenomenon has been widely attributed to two hypotheses that are not mutually exclusive

A 2026 systematic review and meta-analysis of randomized controlled trials confirmed that GLP-1 receptor agonists produce clinically meaningful weight loss across diverse patient populations (Ahmad et al., 2026, PMID: 41824845)

Semaglutide troche is formulated as a GLP-1 receptor agonist